PersonGen BioTherapeutics
PrivateLast Round
Series B
Jan 1, 2022
Total Funding Raised
$51.6M
Company Overview
PersonGen BioTherapeutics is a biotechnology company that develops innovative cellular immunotherapies, including CAR-T cell therapies, for the treatment of cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PersonGen BioTherapeutics Comps
Public and private peers based on sector, stage, and business model.
PersonGen BioTherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 1, 2022 | ||||
| Series A | May 1, 2021 | ||||
| Strategic | Nov 11, 2015 | ||||
| Angel | Aug 1, 2012 |
PersonGen BioTherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Shenzhen Sangel Venture Capital | Series A |
| YuanBio Venture Capital | Series A |
PersonGen BioTherapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about PersonGen BioTherapeutics's valuation, stock price, and market status.
